{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:54:53Z","timestamp":1792637693569,"version":"4.5.0"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004493","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000}}],"reference-count":63,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["3U24TR002306-04S2"],"award-info":[{"award-number":["3U24TR002306-04S2"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nirmatrelvir with ritonavir (Paxlovid) is indicated for patients with Coronavirus Disease 2019 (COVID-19) who are at risk for progression to severe disease due to the presence of one or more risk factors. Millions of treatment courses have been prescribed in the United States alone. Paxlovid was highly effective at preventing hospitalization and death in clinical trials. Several studies have found a protective association in real-world data, but they variously used less recent study periods, correlational methods, and small, local cohorts. Their estimates also varied widely. The real-world effectiveness of Paxlovid remains uncertain, and it is unknown whether its effect is homogeneous across demographic strata. This study leverages electronic health record data in the National COVID Cohort Collaborative\u2019s (N3C) repository to investigate disparities in Paxlovid treatment and to emulate a target trial assessing its effectiveness in reducing severe COVID-19 outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      This target trial emulation used a cohort of 703,647 patients with COVID-19 seen at 34 clinical sites across the United States between April 1, 2022 and August 28, 2023. Treatment was defined as receipt of a Paxlovid prescription within 5 days of the patient\u2019s COVID-19 index date (positive test or diagnosis). To emulate randomization, we used the clone-censor-weight technique with inverse probability of censoring weights to balance a set of covariates including sex, age, race and ethnicity, comorbidities, community well-being index (CWBI), prior healthcare utilization, month of COVID-19 index, and site of care provision. The primary outcome was hospitalization; death was a secondary outcome. We estimated that Paxlovid reduced the risk of hospitalization by 39% (95% confidence interval (CI) [36%, 41%];\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), with an absolute risk reduction of 0.9 percentage points (95% CI [0.9, 1.0];\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), and reduced the risk of death by 61% (95% CI [55%, 67%];\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), with an absolute risk reduction of 0.2 percentage points (95% CI [0.1, 0.2];\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). We also conducted stratified analyses by vaccination status and age group. Absolute risk reduction for hospitalization was similar among patients that were vaccinated and unvaccinate, but was much greater among patients aged 65+ years than among younger patients. We observed disparities in Paxlovid treatment, with lower rates among black and Hispanic or Latino patients, and within socially vulnerable communities. This study\u2019s main limitation is that it estimates causal effects using observational data and could be biased by unmeasured confounding.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study of Paxlovid\u2019s real-world effectiveness, we observed that Paxlovid is effective at preventing hospitalization and death, including among vaccinated patients, and particularly among older patients. This remains true in the era of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron subvariants. However, disparities in Paxlovid treatment rates imply that the benefit of Paxlovid\u2019s effectiveness is not equitably distributed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004493","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T15:13:10Z","timestamp":1737126790000},"page":"e1004493","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effect of nirmatrelvir\/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C"],"prefix":"10.1371","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0063-368X","authenticated-orcid":true,"given":"Abhishek","family":"Bhatia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-527X","authenticated-orcid":true,"given":"Alexander J.","family":"Preiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4198-7502","authenticated-orcid":true,"given":"Xuya","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8095-547X","authenticated-orcid":true,"given":"M. Daniel","family":"Brannock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Caleb","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6979-1766","authenticated-orcid":true,"given":"Robert F.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1245-2034","authenticated-orcid":true,"given":"Hannah","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2494-317X","authenticated-orcid":true,"given":"Elaine","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3722-8928","authenticated-orcid":true,"given":"Elizabeth P.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9134-6370","authenticated-orcid":true,"given":"Hemalkumar B.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3647-1045","authenticated-orcid":true,"given":"Charisse","family":"Madlock-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0531-7165","authenticated-orcid":true,"given":"Kenneth J.","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5437-2545","authenticated-orcid":true,"given":"Christopher G.","family":"Chute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9114-8737","authenticated-orcid":true,"given":"Melissa","family":"Haendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2723-5902","authenticated-orcid":true,"given":"Richard","family":"Moffitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6840-9756","authenticated-orcid":true,"given":"Emily R.","family":"Pfaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the N3C Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"pmed.1004493.ref001","author":"WHO Coronavirus (COVID-19) Dashboard","year":"2023","journal-title":"Accessed"},{"key":"pmed.1004493.ref002","unstructured":"Center for Drug Evaluation, Research. FDA Updates on Paxlovid for Health Care Providers. In: U.S. Food and Drug Administration [Internet]. FDA; [accessed 2023 Mar 26]. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-updates-paxlovid-health-care-providers."},{"key":"pmed.1004493.ref003","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.","volume":"386","author":"J Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"pmed.1004493.ref004","first-page":"830","article-title":"Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment\u2014California.","author":"DE Malden","year":"2022"},{"key":"pmed.1004493.ref005","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/ciac687","article-title":"Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19).","volume":"76","author":"TC-F Yip","year":"2023","journal-title":"Clin Infect Dis"},{"key":"pmed.1004493.ref006","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients","volume":"76","author":"R Najjar-Debbiny","year":"2023","journal-title":"Clin Infect Dis"},{"key":"pmed.1004493.ref007","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2204919","article-title":"Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge","volume":"387","author":"R Arbel","year":"2022","journal-title":"N Engl J Med"},{"key":"pmed.1004493.ref008","article-title":"Covid Drug Paxlovid Now Less Effective Than In Early Trials\u2014But It\u2019s Still Great At Preventing Death.","author":"W. Skipworth","year":"2023","journal-title":"Forbes Magazine"},{"key":"pmed.1004493.ref009","doi-asserted-by":"crossref","first-page":"e2335077","DOI":"10.1001\/jamanetworkopen.2023.35077","article-title":"Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections","volume":"6","author":"D-Y Lin","year":"2023","journal-title":"JAMA Netw Open"},{"key":"pmed.1004493.ref010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/M22-2141","article-title":"Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System: A Population-Based Cohort Study","volume":"176","author":"S Dryden-Peterson","year":"2023","journal-title":"Ann Intern Med"},{"key":"pmed.1004493.ref011","doi-asserted-by":"crossref","first-page":"e073312","DOI":"10.1136\/bmj-2022-073312","article-title":"Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records","volume":"381","author":"Y Xie","year":"2023","journal-title":"BMJ"},{"key":"pmed.1004493.ref012","article-title":"DU Study Finds History of TBI Likely Worsens Long COVID Symptoms.","author":"N. Anschuetz","year":"2023","journal-title":"University of Denver"},{"key":"pmed.1004493.ref013","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1161\/STROKEAHA.123.042360","article-title":"Traumatic Brain Injury and Long-Term Risk of Stroke Among US Military Veterans","volume":"54","author":"ALC Schneider","year":"2023","journal-title":"Stroke"},{"key":"pmed.1004493.ref014","first-page":"19","article-title":"Asbestos Exposure and Severity of COVID-19","author":"G Granados","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"pmed.1004493.ref015","article-title":"Why should veterans diagnosed with mesothelioma seek legal help? Mesothelioma Center.","author":"A. Munz","year":"2022","journal-title":"Vital Services for Cancer Patients & Families"},{"key":"pmed.1004493.ref016","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/j.1475-6773.2005.00448.x","article-title":"Measurement in Veterans Affairs Health Services Research: veterans as a special population.","volume":"40","author":"RO Morgan","year":"2005","journal-title":"Health Serv Res."},{"key":"pmed.1004493.ref017","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/ajt.16843","article-title":"Use of anti-spike monoclonal antibodies in kidney transplant recipients with COVID-19: Efficacy, ethnic and racial disparities.","volume":"22","author":"EJ Klein","year":"2022","journal-title":"Am J Transplant."},{"key":"pmed.1004493.ref018","doi-asserted-by":"crossref","first-page":"96","DOI":"10.15585\/mmwr.mm7103e1","article-title":"Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19\u2014United States, March 2020-August 2021.","volume":"71","author":"JL Wiltz","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"pmed.1004493.ref019","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s11606-022-07603-4","article-title":"Disparities in COVID-19 Monoclonal Antibody Delivery: a Retrospective Cohort Study","volume":"37","author":"E-L Wu","year":"2022","journal-title":"J Gen Intern Med"},{"key":"pmed.1004493.ref020","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.15585\/mmwr.mm7143a2","article-title":"Racial and Ethnic Disparities in Outpatient Treatment of COVID-19\u2014United States, January-July 2022.","volume":"71","author":"TK Boehmer","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"pmed.1004493.ref021","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available","volume":"183","author":"MA Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"pmed.1004493.ref022","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target Trial Emulation: A Framework for Causal Inference From Observational Data","volume":"328","author":"MA Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"key":"pmed.1004493.ref023","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/jamia\/ocaa196","article-title":"The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment.","volume":"28","author":"MA Haendel","year":"2021","journal-title":"J Am Med Inform Assoc."},{"key":"pmed.1004493.ref024","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/jamia\/ocab217","article-title":"Synergies between centralized and federated approaches to data quality: a report from the national COVID cohort collaborative.","volume":"29","author":"ER Pfaff","year":"2022","journal-title":"J Am Med Inform Assoc"},{"key":"pmed.1004493.ref025","unstructured":"Phenotype_Data_Acquisition: The repository for code and documentation produced by the N3C Phenotype and Data Acquisition workstream. Github. Available from: https:\/\/github.com\/National-COVID-Cohort-Collaborative\/Phenotype_Data_Acquisition."},{"key":"pmed.1004493.ref026","first-page":"335","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies.","author":"British Medical Journal Publishing Group","year":"2007","journal-title":"BMJ"},{"key":"pmed.1004493.ref027","volume-title":"Interim Clinical Considerations for COVID-19 Treatment in Outpatients.","author":"CDC","year":"2023"},{"key":"pmed.1004493.ref028","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/jpc.15811","article-title":"COVID-19 in children. II: Pathogenesis, disease spectrum and management","volume":"58","author":"AR Howard-Jones","year":"2022","journal-title":"J Paediatr Child Health"},{"key":"pmed.1004493.ref029","article-title":"Pediatric Nirmatrelvir\/Ritonavir Prescribing Patterns During the COVID-19 Pandemic.","author":"S Bose-Brill","year":"2022","journal-title":"medRxiv"},{"key":"pmed.1004493.ref030","unstructured":"Paxlovid Drug-Drug Interactions. In: COVID-19 Treatment Guidelines [Internet]. [Accessed 2024 May 7]. Available from: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antivirals-including-antibody-products\/ritonavir-boosted-nirmatrelvir\u2014paxlovid-\/paxlovid-drug-drug-interactions\/."},{"key":"pmed.1004493.ref031","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses.","volume":"79","author":"MA Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"pmed.1004493.ref032","first-page":"574","article-title":"Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers.","volume":"216","author":"G Hripcsak","year":"2015","journal-title":"Stud Health Technol Inform."},{"key":"pmed.1004493.ref033","unstructured":"SPH and Sharecare Release Community Well-Being Rankings. [Accessed 2023 Mar 30]. Available from: https:\/\/www.bu.edu\/sph\/news\/articles\/2020\/sph-and-sharecare-release-community-well-being-rankings\/."},{"key":"pmed.1004493.ref034","doi-asserted-by":"crossref","first-page":"k182","DOI":"10.1136\/bmj.k182","article-title":"How to estimate the effect of treatment duration on survival outcomes using observational data","volume":"360","author":"MA Hern\u00e1n","year":"2018","journal-title":"BMJ"},{"key":"pmed.1004493.ref035","first-page":"6","article-title":"Dynamic regime marginal structural mean models for estimation of optimal dynamic treatment regimes, Part I: main content.","author":"L Orellana","year":"2010","journal-title":"Int J Biostat."},{"key":"pmed.1004493.ref036","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/01.ede.0000135174.63482.43","article-title":"A structural approach to selection bias.","volume":"15","author":"MA Hern\u00e1n","year":"2004","journal-title":"Epidemiology"},{"key":"pmed.1004493.ref037","doi-asserted-by":"crossref","first-page":"i189","DOI":"10.1136\/bmj.i189","article-title":"Inverse probability weighting","volume":"352","author":"MA Mansournia","year":"2016","journal-title":"BMJ"},{"key":"pmed.1004493.ref038","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/0962280216628900","article-title":"Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator.","volume":"27","author":"S Willems","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"pmed.1004493.ref039","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10985-015-9335-y","article-title":"Does Cox analysis of a randomized survival study yield a causal treatment effect?","volume":"21","author":"OO Aalen","year":"2015","journal-title":"Lifetime Data Anal"},{"key":"pmed.1004493.ref040","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","article-title":"Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease","volume":"19","author":"MA Hern\u00e1n","year":"2008","journal-title":"Epidemiology"},{"key":"pmed.1004493.ref041","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12916-017-0875-8","article-title":"Number needed to treat (NNT) in clinical literature: an appraisal.","volume":"15","author":"D Mendes","year":"2017","journal-title":"BMC Med"},{"key":"pmed.1004493.ref042","unstructured":"Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR). [Accessed 2023 Mar 31]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05011513."},{"key":"pmed.1004493.ref043","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJMoa2309003","article-title":"Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19","volume":"390","author":"H Jennifer","year":"2024","journal-title":"N Engl J Med"},{"key":"pmed.1004493.ref044","volume-title":"Data Definitions for COVID-19 Vaccinations in the United States.","author":"CDC","year":"2023"},{"key":"pmed.1004493.ref045","article-title":"Long COVID Risk and Pre-COVID Vaccination: An EHR-Based Cohort Study from the RECOVER Program.","author":"MD Brannock","year":"2022","journal-title":"medRxiv"},{"key":"pmed.1004493.ref046","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1111\/jgs.18380","article-title":"Effects of Medicare eligibility and enrollment at age 65 among immigrants and US-born residents.","volume":"71","author":"S Park","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"pmed.1004493.ref047","unstructured":"Creators N3C Publication Committee N3C Governance Committee. N3C and Tenant Pilot Attribution and Publication Principles. doi: 10.5281\/zenodo.10698093"},{"key":"pmed.1004493.ref048","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"ME Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"pmed.1004493.ref049","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"H Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"pmed.1004493.ref050","doi-asserted-by":"crossref","first-page":"e039886","DOI":"10.1136\/bmjopen-2020-039886","article-title":"US-county level variation in intersecting individual, household and community characteristics relevant to COVID-19 and planning an equitable response: a cross-sectional analysis","volume":"10","author":"T Chin","year":"2020","journal-title":"BMJ Open"},{"key":"pmed.1004493.ref051","doi-asserted-by":"crossref","first-page":"458","DOI":"10.15585\/mmwr.mm6915e3","article-title":"Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019\u2014COVID-NET, 14 States, March 1\u201330, 2020.","volume":"69","author":"S Garg","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"pmed.1004493.ref052","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0140-6736(20)30893-X","article-title":"COVID-19 exacerbating inequalities in the US","volume":"395","author":"A van Dorn","year":"2020","journal-title":"Lancet"},{"key":"pmed.1004493.ref053","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.amepre.2020.04.003","article-title":"Disparities in the Population at Risk of Severe Illness From COVID-19 by Race\/Ethnicity and Income.","volume":"59","author":"MA Raifman","year":"2020","journal-title":"Am J Prev Med."},{"key":"pmed.1004493.ref054","doi-asserted-by":"crossref","first-page":"m1483","DOI":"10.1136\/bmj.m1483","article-title":"Covid-19: Black people and other minorities are hardest hit in US","volume":"369","author":"O. Dyer","year":"2020","journal-title":"BMJ"},{"key":"pmed.1004493.ref055","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1001\/jama.2020.8598","article-title":"COVID-19 and Racial\/Ethnic Disparities","volume":"323","author":"M Webb Hooper","year":"2020","journal-title":"JAMA"},{"key":"pmed.1004493.ref056","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19","volume":"181","author":"S Gupta","year":"2021","journal-title":"JAMA Intern Med"},{"key":"pmed.1004493.ref057","doi-asserted-by":"crossref","first-page":"e200452","DOI":"10.1001\/jamanetworkopen.2020.0452","article-title":"Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.","volume":"3","author":"LC Petito","year":"2020","journal-title":"JAMA Netw Open."},{"key":"pmed.1004493.ref058","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1038\/s41591-019-0597-x","article-title":"Avoidable flaws in observational analyses: an application to statins and cancer","volume":"25","author":"BA Dickerman","year":"2019","journal-title":"Nat Med"},{"key":"pmed.1004493.ref059","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1513\/AnnalsATS.201903-241OC","article-title":"Emulating a Novel Clinical Trial Using Existing Observational Data","volume":"16","author":"AJ Admon","year":"2019","journal-title":"Predicting Results of the PreVent Study. Ann Am Thorac Soc"},{"key":"pmed.1004493.ref060","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jclinepi.2011.01.001","article-title":"Administrative database research infrequently used validated diagnostic or procedural codes.","volume":"64","author":"C van Walraven","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"pmed.1004493.ref061","first-page":"1035","article-title":"Strategies for handling missing data in electronic health record derived data.","volume":"1","author":"BJ Wells","year":"2013","journal-title":"EGEMS (Wash DC)."},{"key":"pmed.1004493.ref062","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/EDE.0000000000000794","article-title":"Out-of-system Care and Recording of Patient Characteristics Critical for Comparative Effectiveness Research.","volume":"29","author":"KJ Lin","year":"2018","journal-title":"Epidemiology."},{"key":"pmed.1004493.ref063","first-page":"286","article-title":"Evaluating Risk-Prediction Models Using Data from Electronic Health Records.","volume":"10","author":"LE Wang","year":"2016","journal-title":"Ann Appl Stat."}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004493","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T13:58:28Z","timestamp":1738591108000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004493"}},"subtitle":[],"editor":[{"given":"Aaloke","family":"Mody","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004493","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]}}}